Anti-inflammatory and analgesic activity of indolyl quinazolones and their congeners.
6,8-Disubstituted-2-methyl-3-[2-substituted-indol-3-yl-methyl(ene)imino] -quinazoline-4(3H)-ones (III), 6,8-disbustituted-2-methyl-3-[2-substituted-indol-3-yl methyl amino]-quinazoline-4(3H)-ones (IV), 6,8-disubstituted-2-methyl-2-[5-(2-substituted-indol-3-yl)-thiazolidine- 3- one]quinazoline-4(3H)-ones (V), propionic acid derivative of 6,8-disubstituted-2-methyl-3-[5-(2-substituted indol-3-yl)-thiazolidine-3-one]-quinazoline-4(3H)-ones (VI), 6,8-disubstituted-2-methyl-3-[5-(2-substituted-indol-3-yl)-2-substituted benzylidine-thiazolidine-3-one]-quinazoline 4(3H)-ones (VII), 6,8-disubstituted-2-methyl-3-[2-substituted-indol-3-yl-4- chloroazetidine-1-one]-quinazoline-4-(3H)-ones (VIII), and 6,8-disubstituted-2-methyl-3-[2-substituted-indol-3- yl-alpha-arylazo methylimino]-quinazoline-4(3H)-ones (IX) were synthesized and evaluated for their anti-inflammatory activity against carrageenin induced paw oedema. The compounds found potent were further tested for their anti-writhmogenic activity in albino mice. The compounds exhibiting significant anti-inflammatory activity also showed marked protection against aconitine induced writhing response. The low toxicity of the potent compounds was also reflected by their high approximate LD50 values.